Telix Pharmaceuticals Limited
ACN 616 620 369
55 Flemington Road
North Melbourne
Victoria, 3051
Australia

ASX ANNOUNCEMENT

Results Announcement for the Half-Year Ended 30 June 2024

Melbourne (Australia) – 22 August 2024. Telix Pharmaceuticals Limited (ASX: TLX).

In accordance with ASX Listing Rule 4.2A, please find attached the following documents for the half-year ended 30 June 2024:

- Appendix 4D;
- Directors' report; and
- Interim financial report.

These documents should be read in conjunction with the Telix Pharmaceuticals Limited 2023 Annual Report, accessible on the Company's website at https://telixpharma.com/investor-centre/financial-reports-presentations/.

Authorised for lodgement by:

Genevieve Ryan
Company Secretary

For further information, please contact:

Telix Investor Relations

Ms. Kyahn Williamson
Telix Pharmaceuticals Limited
SVP Investor Relations and Corporate Communications
Email: kyahn.williamson@telixpharma.com

Telix Pharmaceuticals Limited
ACN 616 620 369
55 Flemington Rd
North Melbourne
Victoria, 3051
Australia

Appendix 4D

Report for the half-year ended 30 June 2024

Results announcement to the market

Current Reporting Period:	**30 June 2024**
Previous Corresponding Reporting Period:	30 June 2023

	6 months to 30 June 2024	**Change**	**Change**	**Change**	**6 months to 30 June 2023**
	$'000		**$'000**	**%**	**$'000**
Revenue from contracts with customers	363,964	Improved	143,130	65%	220,834
Profit/(loss) after income tax for the half-year attributable to members	29,654	Improved	43,974	(307%)	(14,320)
Total comprehensive profit/(loss) for the half-year attributable to members	41,553	Improved	51,571	(515%)	(10,018)

No dividend was proposed or paid. Should any dividends be paid in the future, no assurances can be given as to the level of franking credits attaching to such dividends.

	30 June 2024	**30 June 2023**
	Cents	**Cents**
Profit/(loss) per share	9.0	(4.5)
Net tangible (liabilities)/assets per share	(9.7)	3.6

Events subsequent to the end of the half-year

Refer to note 17 of the Interim financial report for details of events subsequent to 30 June 2024 and at the date of this report.

Explanation of results

For further explanation of the results, please refer to the accompanying ASX release and the Financial Review in the Directors' report that is within the Interim Report. This information should be read in conjunction with the most recent Annual Report (for the financial year ended 31 December 2023).

Other information required by Listing Rule 4.2A

The remainder of the information requiring disclosure to comply with Listing Rule 4.2A is contained in the attached Directors' report, Interim financial report and ASX release.

Auditor's review

This report is based on the Interim financial report for the half-year ended 30 June 2024 of Telix Pharmaceuticals Limited and its controlled entities, which has been reviewed by PricewaterhouseCoopers (PwC). The Independent auditor's review report provided by PwC is included in the Interim financial report.

The Appendix 4D and Interim financial report for the half-year ended 30 June 2024 have been approved for release by the Board of Directors.

Genevieve Ryan
Company Secretary
22 August 2024

Telix Pharmaceuticals Limited

ACN 616 620 369

Interim Report
30 June 2024

Lodged with the ASX under Listing Rule 4.2A

Contents

Directors' report

Directors

The Board of Directors of Telix Pharmaceuticals Limited is pleased to present its report on the consolidated entity (Group) for the half-year ended 30 June 2024 (H1 2024). The Group consists of Telix Pharmaceuticals Limited (Telix or the Company) and its wholly owned subsidiaries.

The following persons were Directors of Telix Pharmaceuticals Limited during the half-year ended 30 June 2024 and up to the date of this report:

Name	Title
H Kevin McCann AO	Chairman
Christian Behrenbruch PhD	Managing Director and Group Chief Executive Officer
Andreas Kluge MD PhD	Non-Executive Director
Jann Skinner	Non-Executive Director
Mark Nelson PhD	Non-Executive Director
Tiffany Olson	Non-Executive Director

Half-year in review

Financial highlights

$364.0M
Total Group revenue
Up $143.2M or 65%from H1 2023

66%
Gross margin
Compared to 63% in H1 2023

$29.7M
Net profit after tax
Improved by $44.0M from a loss of $14.3M in H1 2023

$137.1M
Adjusted EBITDAR
Up $55.8M or 69% from $81.3M in H1 2023

Financial review

Telix continues to grow

Revenue improved to $364.0 million for the half-year ended 30 June 2024, an increase of $143.2 million, or 65% compared to $220.8 million for the prior comparable period. The majority of revenue was from sales of Illuccix® in the United States (U.S.) in its second full year of commercial sales.

Gross margin continued to improve to end at 66% for the half-year ended 30 June 2024 (up from 63% in H1 2023), supported by a stable selling price of Illuccix® and disciplined cost control.

Total revenue and gross margin by half-year



Reported half-year profit after tax attributable to Telix shareholders was $29.7 million, compared to a net loss of $14.3 million in H1 2023. This includes costs associated with the withdrawn U.S. initial public offering (IPO) of $7.6 million. The increase in profitability demonstrates our ability to build a sustainable business while investing for growth and advancement of late-stage pipeline assets.

Adjusted earnings before, interest, tax, depreciation and amortisation (Adjusted EBITDA) was $57.5 million, improved by $22.8 million or 66% when compared to $34.7 million in the prior comparable period.

The Group generated cash from operating activities of $39.1 million, an improvement of $25.8 million from H1 2023.

Commercial

	H1 2024	% of revenue	H1 2023	% of revenue
	$M		$M	
Revenue (product)	358.8		218.5	
Cost of sales	(124.9)		(81.8)	
Gross profit	**233.9**	**65%**	**136.7**	**63%**
Selling and marketing expenses	(37.2)	(10%)	(24.2)	(11%)
Manufacturing and distribution costs	(5.1)	(1%)	(3.1)	(1%)
General and administration costs	(16.9)	(5%)	(14.0)	(6%)
Other losses (net)	0.2	0%	(1.3)	(1%)
Operating profit	**174.9**	**49%**	**94.1**	**43%**
Group adjusted EBITDAR	**137.1**		**81.3**	

Maturation of cost base delivering higher margins

U.S. sales from Illuccix® was the main driver with a 64% increase in revenue compared to H1 2023, reflecting continued growth in sales volume and market share gains. Average daily demand for doses continued to grow throughout the first half of the year.

Gross margin steadily improved during the half-year to end at 65% (up from 63% in the prior comparable period), reflecting optimised manufacturing and distribution costs.

Sales and marketing expenses were $37.2 million for the half-year ended 30 June 2024, an increase of $13.0 million, or 54%, compared to $24.2 million for H1 2023. This increase was primarily driven by increased investment in salesforce operations, effectively deployed to drive higher sales volumes of Illuccix®. Selling and marketing expenses continue to reduce as a percentage of revenue, indicative of revenue growth exceeding cost base growth and expenditure control.

Manufacturing and distribution costs were $5.1 million for the half-year ended 30 June 2024, an increase of $2.0 million, or 65%, compared to $3.1 million for H1 2023, primarily driven by the increased volume of sales.

General and administration costs were $16.9 million for the half-year ended 30 June 2024, an increase of $2.9 million, or 21%, compared to $14.0 million for H1 2023. This increase was primarily driven by an increase in infrastructure to support the expansion of services assisting commercial operations in each region.

Operating profit as a percentage of revenue improved by 6% reflecting the strength of the commercial business and effective cost control.

Group adjusted earnings before interest, tax, depreciation, amortisation and research and development (Adjusted EBITDAR) was $137.1 million, improved significantly, from $81.3 million in H1 2023. This metric demonstrates the profitability of the commercial organisation and strong revenue growth from Illuccix® during the period.

Profit/(loss) before tax and Adjusted EBITDAR by half-year



Product development

Projects	H1 2024	% of total	H1 2023	% of total
	$M		$M	
Late-stage diagnostics	34.0	41%	18.5	38%
Therapeutics and other assets	24.3	29%	11.8	24%
Total external R&D	**58.3**		**30.3**	
Employment costs	19.3	23%	14.7	30%
General and administration costs	6.3	8%	3.7	8%
Total R&D expenditure	**83.9**		**48.7**	

Preparing to launch three new imaging agents in the U.S.

Research and development (R&D) investment for the half-year ended 30 June 2024 was predominantly focused on preparing for the commercial launch of late-stage diagnostic assets (TLX250-CDx or Zircaix®[1], TLX101-CDx or Pixclara®[1] and TLX007-CDx) including commercial manufacturing process qualification and validation, U.S. Food and Drug Administration (FDA) filing fees and early access programs. R&D was also directed towards clinical manufacturing for the Phase III ProstACT GLOBAL trial.

Total investment in R&D was $83.9 million for the half-year, an increase of $35.2 million, or 72%, compared to $48.7 million for H1 2023. Approximately 29% of R&D expenses were directed towards progressing the Group's therapeutic pipeline.

Overall investment in therapeutics and other assets totalled $24.3 million (H1 2023: $11.8 million) This included, late-stage therapeutic asset investment directed towards clinical manufacturing and progressing the Phase III ProstACT GLOBAL trial.

Investment in late-stage diagnostic assets was $34.0 million (H1 2023: $18.5 million), comprising:

- commercial manufacturing process qualification and validation
- filing fees for TLX250-CDx (Zircaix®[1]) biologics license application (BLA) submission and new drug application (NDA) submission for TLX007-CDx with FDA, and
- commercial launch preparation and early access programs.

Employment and general and administration costs reflect increased activity in our late-stage assets.

Medical devices

The Medical devices operating segment represents the Group's activities associated with developing complementary artificial intelligence (AI) and robotic technologies. The costs incurred during H1 2024 reflect the operations of Lightpoint Surgical, Dedicaid and QDOSE, and the development of AI-enabled molecular imaging and guided robotic surgical technologies.

Manufacturing services

During H1 2024 the Group acquired ARTMS Inc (ARTMS). and IsoTherapeutics Group (IsoTherapeutics) as we continue to invest in the vertical integration of our business. We believe this is an essential foundation for long-term commercial success across the breadth of our product pipeline.

The increase in costs during H1 2024 reflects impact of the newly acquired businesses and higher costs associated with the Brussels South manufacturing facility in preparing the facility for commerical production.

1. Brand name subject to final regulatory approval.

Cash balance and activities

Cash and cash equivalents were $118.8 million as at 30 June 2024 (31 December 2023: $123.2 million) with positive net operating cash flow consistently delivered.

On 30 July 2024 the Group received net proceeds of approximately $635.0 million from the issue of convertible bonds on the Singapore Exchange, maturing 2029. The convertible bonds are convertible into fully paid ordinary shares in Telix Pharmaceuticals Limited, refer to the 'Subsequent events' section below and note 17 for further details.

Closing cash reconciliation



Operating activities

Net cash generated from operating activities was $39.1 million (H1 2023: $13.3 million). The primary sources of cash from operating activities were collections from sales of Illuccix® of $343.3 million (H1 2023: $195.3 million). The improved customer receipts reflect sales growth and improved debtor management during H1 2024.

The primary uses of cash in operating activities were payments to suppliers and employees of $298.2 million (H1 2023: $176.3 million), including manufacturing and R&D expenditures, selling and marketing efforts for Illuccix®, employee costs and income taxes paid (primarily in the U.S.) of $6.8 million (H1 2023: $5.9 million).

Investing activities

Net cash used in investing activities of $45.8 million (H1 2023: $2.9 million) mainly comprised payments for:

- $2.0 million for investments in financial assets
- $11.7 million for the acquisition of QSAM Biosciences, Inc (QSAM)
- $4.7 million (H1 2023: $3.0 million) for the buildout of our manufacturing facility TMS Brussels South
- $4.2 million for the purchases of Ytterbium, and
- $23.2 million for the acquisitions of ARTMS and IsoTherapeutics.

Financing activities

Net cash provided by financing activities totalled $2.2 million (H1 2023: $4.7 million) comprising $0.6 million (H1 2023: $2.9 million) received from the exercise of options previously granted to employees, net proceeds received from borrowings of $2.3 million (H1 2023: $2.5 million) related to the loan facilities provided for the construction of TMS Brussels South and $0.7 million (H1 2023: $0.7 million) paid for lease liabilities.

1. Brand name subject to final regulatory approval.

Operational highlights

Review of operations

Telix has articulated a clear growth strategy to deliver benefits to patients and shareholders through the advancement of its therapeutic and diagnostic portfolio of commercial and clinical stage products, robust supply chain and manufacturing, and continued innovation. The key focus areas and progress to date in the half-year ended 30 June 2024 are outlined in the table below.

Growth strategy	Focus areas	Progress in 2024
Grow Illuccix® revenue globally	Focus on driving adoption and increasing market share of Illuccix® in our commercial markets, including the U.S. Expand into new geographies through submission of new product marketing applications	• Illuccix® global revenue $357.9 million up 64% on H1 2023[1] • European Union (EU) marketing authorisation application (MAA): All regulator questions raised during standard review "clock-stop" period have been addressed[2] • United Kingdom (UK) MAA: Regulator's assessment report received subsequent to reporting period, with no substantive issues raised • EU and UK MAA decisions expected in H2 2024 • Brazil MAA: In final stages of regulatory review, approval decision anticipated during Q3 2024[2] • Pivotal Phase III registration study in China intended to bridge to FDA approval of Illuccix®: Surpassed 75% enrolment[3]
Commercialise the precision medicine (diagnostics) portfolio	Advance regulatory filings for three additional diagnostic imaging agents	**TLX007-CDx (novel PSMA[4] imaging agent)** • U.S. NDA accepted for filing, PDUFA[5] goal date 24 March 2025 **TLX101-CDx (Pixclara®[6]) for positron emission tomography (PET) imaging of glioma (brain cancer)** • Fast Track designation granted by FDA[7] • Positive pre-NDA meeting with the FDA, NDA being finalised for submission in Q3 2024 • Expanded access program cleared by FDA to commence in U.S.[8] **TLX250-CDx (Zircaix®[6]) for PET imaging of clear cell renal cell carcinoma (ccRCC)** • BLA on track for resubmission to the FDA in Q4 2024[9] • Expanded access and compassionate use programs dosing patients in the U.S., EU and Australia • Included in European Association of Urology (EAU) Guidelines for the first time as an emerging technology[10] • ZIRCON Phase III study: First peer review manuscript accepted for publication • New studies launched exploring indication expansion: Staging and recurrence, surveillance[11]

1. Includes pre-commercial sales from investigational, clinical trial, magisterial and compassionate use in accordance with local laws and regulations (not as a commercial diagnostic imaging product sold for routine clinical practice).
2. Telix ASX disclosure 18 July 2024.
3. ClinicalTrials.gov ID: NCT05847348.
4. Prostate-specific membrane antigen.
5. Prescription Drug User Fee Act.
6. Brand name subject to final regulatory approval.
7. Telix ASX disclosure 16 April 2024.
8. Telix media release 29 July 2024.
9. FDA has requested further validation for the TLX250-CDx BLA filing to advance to full review. Telix ASX disclosure 31 July 2024.
10. EAU Guidelines on Renal Cell Carcinoma (April 2024).
11. ClinicalTrials.gov ID: NCT06447103.

Advance our late-stage therapeutic pipeline

Deliver on clinical milestones across core therapy programs in prostate, kidney, brain and musculoskeletal cancers

TLX591 (^{177}Lu rosopatamab tetraxetan)

- ProstACT SELECT: Reported median radiographic progression-free survival (rPFS) of 8.8 months, strong efficacy signal[1]
- ProstACT GLOBAL Phase III study:
  - Investigational New Drug (IND) application cleared by FDA
  - Multiple U.S. sites being activated and preparing to dose first patients
  - Patient recruitment continuing in Asia Pacific

TLX592 (^{225}Ac-RADmAb®)

- CUPID study delivers successful proof-of-concept for targeted alpha therapy in prostate cancer[2]

TLX250 (^{177}Lu girentuximab)

- STARLITE-2 Phase II investigator-initiated trial (IIT) of TLX250 in combination with immunotherapy[3]: Continuing to dose patients, on track for data readout in 2024
- STARSTRUCK Phase Ib study of TLX250 in combination with peposertib in CAIX-expressing solid tumours[4]: Continuing to dose patients
- STARBURST Phase II study of TLX250-CDx, exploring theranostic utility across a range of solid tumours[5]: Continuing to dose patients

TLX101 (^{131}I-IPA)

- IPAX-2 Phase I study of TLX101 in front-line setting[6]: Second patient cohort expanded, continuing to dose patients
- IPAX-Linz Phase II IIT of TLX101 therapy in refractory setting: Continuing to dose patients, on track to complete enrolment in 2024
- IPAX-1 Phase I study: First peer review manuscript published in Neuro-Oncology Advances[7], restates encouraging early efficacy

TLX300 (-olaratumab)

- Ethics granted to commence a Phase I proof-of-concept therapy trial in soft tissue sarcoma

Expand the future pipeline

Leverage our expertise to identify, evaluate and develop novel targets, clinical applications and manufacturing technologies to build the future pipeline

- Acquisition of QSAM Biosciences Inc. and lead asset, Samarium-153-DOTMP[8]
- Commercial partnership with QDOSE® dosimetry software platform[9]

1. Telix ASX disclosure 31 May 2024.
2. Telix ASX disclosure 21 May 2024.
3. ClinicalTrials.gov ID: NCT05239533.
4. ClinicalTrials.gov ID: NCT05868174.
5. ClinicalTrials.gov ID: NCT05563272.
6. ClinicalTrials.gov ID: NCT05450744.
7. Pichler et al. *Neuro-Oncology Advances*. 2024.
8. Telix ASX disclosure 3 May 2024.
9. Telix media release 19 March 2024.

Vertically integrate manufacturing and supply chain activities

Protect and enhance our ability to serve patients in all global markets and further develop production expertise through in-house manufacturing

- Acquisitions of ARTMS[1] and IsoTherapeutics[2]: Provides greater control over supply chain and self-sufficiency in manufacturing
- Optimal Tracers: Executed development and production validation milestones for key Telix assets, preparing to initiate clinical trial supply for selected U.S. and Asia Pacific based trials
- Telix Manufacturing Solutions (TMS) Brussels South: Hot cell R&D facilities fully operational, ready to supply clinical doses, GMP[3] accreditation inspection Q3 2024

Prospects and likely developments

The future prospects of our growth and operational targets depend on:

- Continued revenue growth of Illuccix®
- Regulatory approvals and successful commercial launches of our diagnostic portfolio, and
- Advancement of our therapeutic pipeline.

More information relating to factors that could affect our future prospects and operational targets is provided in the Managing risk section of our 2023 Annual Report.

Changes to share capital

Total number of shares and options on issue

The Company had the below equity instruments on issue:

	31 December 2023	30 June 2024	At the date of this report
	Number	Number	Number
Shares on issue	323,726,683	334,231,398	334,640,424
Options, PSARs and share rights on issue	14,601,225	20,584,681	20,584,681

Issue of fully paid ordinary shares and rights for acquisitions during the period

The Company completed the following acquisitions during the period, which resulted in the respective issue of fully paid ordinary shares and rights outlined below.

QSAM Biosciences Inc.

On 3 May 2024 Telix completed of the acquisition of QSAM. The purchase price was paid to QSAM shareholders in equity through the issue of 3,671,120 fully paid ordinary Telix shares and the balance paid in cash. 409,026 Telix shares were issued on 4 July 2024, as part of the post completion adjustment holdback and QSAM transaction costs.

In addition to the above, 4,284,000 performance rights have been issued to QSAM shareholders. Each milestone has a fixed dollar amount which can be settled either in cash or shares.

IsoTherapeutics Group LLC

On 9 April 2024 Telix completed the acquisition of IsoTherapeutics Group LLC. The purchase price was paid in equity through the issue of 717,587 fully paid ordinary Telix shares at $12.42 per share, with $3,285,000 paid in cash.

ARTMS Inc.

On 11 April 2024 Telix completed the acquisition of radioisotope production technology firm ARTMS Inc. The purchase price was paid in equity through the issue of 5,674,365 fully paid ordinary Telix shares at $12.62 per share, with $24,491,000 paid in cash.

1. Telix ASX disclosure 11 April 2024.
2. Telix ASX disclosure 9 April 2024.
3. Good manufacturing practice.

Exercise of unlisted share options and PSARs for the issue of fully paid ordinary shares

A total of 441,373 fully paid ordinary shares were issued upon exercise of 520,007 unlisted share options during the half-year ended 30 June 2024.

Lapse of unlisted share options

A total of 1,495,100 unlisted share options lapsed, unexercised, during the period.

Issue of unlisted performance share appreciation rights (PSARs) and share rights

During the period a total of 3,714,563 unlisted performance share incentive rights (PSIRs), PSARs and rights were issued to employees. This included 144,037 PSARs to the Managing Director and Group Chief Executive Officer, Christian Behrenbruch following shareholder approval at the Company's AGM held on 22 May 2024. These PSARs have a notional exercise price of $11.94 per PSAR. PSARs have a three-year performance measurement period. The vesting is subject to achievement of published performance measures, following the completion of the performance measurement period.

As at 30 June 2024, the number of equity incentives on issue under the Equity Incentive Plan and issued under exception 13 of Listing Rule 7.2 was 6.2% (31 December 2023: 4.5%)

Issue of convertible bonds

On 30 July 2024 the Group completed the issue of $650,000,000 in convertible bonds due 2029. The convertible bonds are convertible into fully paid ordinary shares in Telix Pharmaceuticals Limited, refer to the 'Subsequent events' section below and note 17 for further details.

Rounding of amounts

The Company is of a kind referred to in ASIC Legislative Instrument 2016/191, relating to the 'rounding off' of amounts in the Directors' report. Amounts in the Directors' report have been rounded off in accordance with the instrument to the nearest thousand dollars, or in certain cases, to the nearest dollar.

Subsequent events

On 30 July 2024 the Group completed the issue of $650,000,000 in convertible bonds due 2029. The convertible bonds are convertible into fully paid ordinary shares in Telix Pharmaceuticals Limited. The initial conversion price of the convertible bonds is $24.78 per share, subject to anti-dilution adjustments set out in the final terms and conditions of the convertible bonds. The convertible bonds will bear interest at a rate of 2.375 per cent per annum. Interest will be payable quarterly in arrear on 30 October, 30 January, 30 April and 30 July in each year, beginning on 30 October 2024. The convertible bonds will mature on or about 30 July 2029, unless redeemed, repurchased, or converted in accordance with their terms. The convertible bonds are listed on the Singapore Exchange Securities Trading Limited (SGX-ST).

The net proceeds of approximately $635,000,000, after transaction costs, are intended to provide funding to bring forward proposed investment in order to accelerate key clinical development programs across the Company's theranostic portfolio. This includes label-expansion studies to expand the market opportunity across Telix's portfolio of diagnostic imaging agents and funding the pivotal trials for kidney and brain cancer therapy programs. In addition, the funding will provide financial flexibility for Telix to explore opportunities and potentially pursue strategically significant M&A transactions and continued investment in global supply chain and manufacturing capabilities.

From the end of the reporting period to the date of this report, no matter or circumstance has arisen which has significantly affected, or may significantly affect, the operations of the Group, the results of those operations or the state of affairs of the Group.

Auditor independence

A statement of independence has been provided by the Company's auditor, PricewaterhouseCoopers, and is included in this report.

This report is made in accordance with a resolution of Directors.

H Kevin McCann AO
Chairman

22 August 2024

Christian Behrenbruch
Managing Director and Group CEO

22 August 2024

Auditor's Independence Declaration

As lead auditor for the review of Telix Pharmaceuticals Limited for the half-year ended 30 June 2024, I declare that to the best of my knowledge and belief, there have been:

(a) no contraventions of the auditor independence requirements of the *Corporations Act 2001* in relation to the review; and

(b) no contraventions of any applicable code of professional conduct in relation to the review.

This declaration is in respect of Telix Pharmaceuticals Limited and the entities it controlled during the period.

Brad Peake
Partner
PricewaterhouseCoopers

Melbourne
22 August 2024

PricewaterhouseCoopers, ABN 52 780 433 757
2 Riverside Quay, SOUTHBANK VIC 3006, GPO Box 1331, MELBOURNE VIC 3001
T: 61 3 8603 1000, F: 61 3 8603 1999, www.pwc.com.au

Interim financial report

Contents

Interim consolidated statement of comprehensive income or loss

for the half-year ended 30 June 2024

	Note	30 June 2024 $'000	30 June 2023 $'000
Continuing operations			
Revenue from contracts with customers	4.1	363,964	220,834
Cost of sales		(124,938)	(81,791)
Gross profit		**239,026**	**139,043**
Research and development costs	4.2	(84,190)	(48,726)
Selling and marketing expenses		(37,311)	(24,171)
Manufacturing and distribution costs		(13,327)	(4,302)
General and administration costs	4.3	(59,341)	(30,315)
Other losses (net)	4.6	(2,870)	(38,159)
Operating profit/(loss)		**41,987**	**(6,630)**
Finance income		1,373	453
Finance costs	4.7	(8,678)	(6,123)
Profit/(loss) before income tax		**34,682**	**(12,300)**
Income tax expense		(5,028)	(2,020)
Profit/(loss) for the half-year		**29,654**	**(14,320)**
Profit/(loss) for the half-year attributable to:			
Owners of Telix Pharmaceuticals Limited		29,654	(14,320)
Other comprehensive income:			
Items that will not be reclassified to profit or loss in subsequent periods:			
Changes in the fair value of investments at fair value through other comprehensive income		(618)	-
Items to be reclassified to profit or loss in subsequent periods:			
Exchange differences on translation of foreign operations		12,517	4,302
Total comprehensive income/(loss) for the half-year		**41,553**	**(10,018)**
Total comprehensive income/(loss) for the half-year attributable to:			
Owners of Telix Pharmaceuticals Limited		41,553	(10,018)

		30 June 2024 Cents	30 June 2023 Cents
Basic earnings/(loss) per share from continuing operations after income tax attributable to the ordinary equity holders of the Company		9.05	(4.51)
Diluted earnings/(loss) per share from continuing operations after income tax attributable to the ordinary equity holders of the Company		8.75	(4.51)

The above interim consolidated statement of comprehensive income or loss is to be read in conjunction with the notes to the interim consolidated financial statements.

Interim consolidated statement of financial position

as at 30 June 2024

	Note	30 June 2024 $'000	31 December 2023 $'000
Current assets			
Cash and cash equivalents		118,837	123,237
Trade and other receivables	5	89,328	64,777
Inventories	6	30,803	17,310
Current tax asset		7,945	7,656
Other current assets		8,348	19,524
Total current assets		**255,261**	**232,504**
Non-current assets			
Financial assets	7	10,462	12,260
Deferred tax assets		36,699	20,452
Property, plant and equipment	8	29,070	23,170
Right-of-use assets		9,185	7,323
Intangible assets	9	399,483	109,663
Other non-current assets		5,798	586
Total non-current assets		**490,697**	**173,454**
Total assets		**745,958**	**405,958**
Current liabilities			
Trade and other payables	11	84,277	81,704
Borrowings		1,900	964
Current tax payable		33,965	19,164
Contract liabilities		12,380	10,995
Lease liabilities		1,880	595
Provisions		734	577
Contingent consideration	12	109,670	37,153
Employee benefit obligations		13,567	13,912
Total current liabilities		**258,373**	**165,064**
Non-current liabilities			
Borrowings		9,952	8,209
Contract liabilities		6,830	12,162
Lease liabilities		8,411	7,677
Deferred tax liabilities		9,615	-
Provisions		7,847	8,004
Contingent consideration	12	40,507	55,601
Employee benefit obligations		449	330
Total non-current liabilities		**83,611**	**91,983**
Total liabilities		**341,984**	**257,047**
Net assets		**403,974**	**148,911**
Equity			
Share capital	14.1	587,408	446,268
Share capital reserve		(68,343)	(62,829)
Foreign currency translation reserve		7,103	(5,414)
Share-based payments reserve	14.2	112,823	35,446
Financial assets at FVOCI reserve		(1,513)	(895)
Accumulated losses		(233,504)	(263,665)
Total equity		**403,974**	**148,911**

The above interim consolidated statement of financial position is to be read in conjunction with the notes to the interim consolidated financial statements.

Interim consolidated statement of changes in equity

for the half-year ended 30 June 2024

	Note	Share capital $'000	Share capital reserve $'000	Foreign currency translation reserve $'000	Share-based payments reserve $'000	Financial assets at FVOCI reserve $'000	Accumulated losses $'000	Total equity $'000
Balance as at 1 January 2024		**446,268**	**(62,829)**	**(5,414)**	**35,446**	**(895)**	**(263,665)**	**148,911**
Profit for the half-year		-	-	-	-	-	29,654	29,654
Other comprehensive income/(loss)		-	-	12,517	-	(618)	-	11,899
Total comprehensive income/(loss) for the half-year		**-**	**-**	**12,517**	**-**	**(618)**	**29,654**	**41,553**
Issue of shares on acquisitions	14.1	134,992	-	-	-	-	-	134,992
Issue of shares on exercise of options	14.1	6,148	(5,514)	-	-	-	-	634
Share based payments to employees	14.2	-	-	-	9,941	-	-	9,941
Share based payments associated with acquisitions	14.2	-	-	-	67,943	-	-	67,943
Transfer on exercise of options	14.2	-	-	-	(507)	-	507	-
		141,140	**(5,514)**	**-**	**77,377**	**-**	**507**	**213,510**
Balance as at 30 June 2024		**587,408**	**(68,343)**	**7,103**	**112,823**	**(1,513)**	**(233,504)**	**403,974**
Balance as at 1 January 2023		**370,972**	**(26,909)**	**(562)**	**9,321**	**-**	**(272,815)**	**80,007**
Loss for the half-year		-	-	-	-	-	(14,320)	(14,320)
Other comprehensive income		-	-	4,302	-	-	-	4,302
Total comprehensive loss for the half-year		**-**	**-**	**4,302**	**-**	**-**	**(14,320)**	**(10,018)**
Issue of shares on acquisitions		1,829	-	-	-	-	-	1,829
Issue of shares on exercise of options		19,095	(16,167)	-	-	-	-	2,928
Share based payments to employees		-	-	-	1,311	-	-	1,311
Transfer on exercise of options		-	-	-	(1,914)	-	1,914	-
		20,924	**(16,167)**	**-**	**(603)**	**-**	**1,914**	**6,068**
Balance as at 30 June 2023		**391,896**	**(43,076)**	**3,740**	**8,718**	**-**	**(285,221)**	**76,057**

The above interim consolidated statement of changes of equity is to be read in conjunction with the notes to the interim consolidated financial statements.

Interim consolidated statement of cash flows
for the half-year ended 30 June 2024

	30 June 2024	30 June 2023
	$'000	$'000
Cash flows from operating activities		
Receipts from customers	343,336	195,330
Payments to suppliers and employees	(298,174)	(176,311)
Income taxes paid	(6,783)	(5,857)
Interest received	1,373	453
Interest paid	(671)	(356)
Net cash generated from operating activities	**39,081**	**13,259**
Cash flows from investing activities		
Payments for investments in financial assets	(1,988)	-
Payments for acquisition of subsidiaries, net of cash acquired	(23,188)	123
Purchases of intangible assets	(11,749)	-
Purchases of other non-current assets	(4,178)	-
Purchases of property, plant and equipment	(4,689)	(3,009)
Payments for contingent consideration	(49)	-
Net cash used in investing activities	**(45,841)**	**(2,886)**
Cash flows from financing activities		
Proceeds from borrowings	2,700	2,484
Repayment of borrowings	(441)	-
Principal element of lease payments	(740)	(711)
Proceeds from issue of shares and other equity	634	2,928
Net cash provided by financing activities	**2,153**	**4,701**
Net (decrease)/increase in cash held	**(4,607)**	**15,074**
Net foreign exchange differences	207	326
Cash and cash equivalents at the beginning of the half-year	123,237	116,329
Cash and cash equivalents at the end of the half-year	**118,837**	**131,729**

The above interim consolidated statement of cash flows is to be read in conjunction with the notes to the interim consolidated financial statements.

Notes to the interim consolidated financial statements

1. Corporate information

Telix Pharmaceuticals Limited (Telix or the Company) is a for profit company incorporated and domiciled in Australia. It is limited by shares that are publicly traded on the Australian Securities Exchange (ASX: TLX). Telix is developing a portfolio of clinical-stage products that address significant unmet medical need in oncology and rare diseases.

Telix is the ultimate parent company of the Telix Pharmaceuticals Group (the Group).

This consolidated financial report of Telix Pharmaceuticals Limited for the half-year ended 30 June 2024 was authorised for issue in accordance with a resolution of the Directors on 22 August 2024.

2. Basis of preparation and changes to the Company's accounting policies

This Interim financial report for the half-year reporting period ended 30 June 2024 has been prepared in accordance with IAS 34 / AASB 134 *Interim Financial Reporting* and the Corporations Act 2001 (Cth). This Interim financial report does not include all the notes of the type normally included in an Annual financial report. Accordingly, this report is to be read in conjunction with the Annual Report for the year ended 31 December 2023 and any public announcements made by Telix Pharmaceuticals Limited during the interim reporting period in accordance with the continuous disclosure requirements of the Corporations Act.

The accounting policies adopted are consistent with those of the previous financial year and corresponding interim reporting period.

A number of new or amended standards became applicable for the current reporting period. The Group did not have to change its accounting policies or make retrospective adjustments as a result of adopting these standards. The Group has identified that there is no impact of new standards issued but not yet applied.

2.1. Going concern

These financial statements have been prepared on the basis that the Company is a going concern.

For the half-year ended 30 June 2024, the Group generated a profit after income tax of $29,654,000 (30 June 2023: loss after income tax of $14,320,000) and cash generated from operating activities of $39,081,000 (30 June 2023: $13,259,000). As at 30 June 2024, whilst in a net current liability position, the net assets of the Group stood at $403,974,000 (31 December 2023: $148,911,000), with cash on hand of $118,837,000 (31 December 2023: $123,237,000).

On 30 July 2024 the Group issued $650,000,000 in convertible bonds, maturing in 2029 and convertible into fully paid ordinary shares, refer to note 17 for further details. The net proceeds, after transaction costs, are intended to provide funding to bring forward proposed investment in order to accelerate key clinical development programs across the Group's theranostic portfolio. This includes label-expansion studies to expand the market opportunity across our portfolio of diagnostic imaging agents and funding the pivotal trials for kidney and brain cancer therapy programs. In addition, the funding will provide financial flexibility for the Group to explore opportunities and potentially pursue strategically significant M&A transactions and continued investment in global supply chain and manufacturing capabilities.

Cash on hand, the net proceeds from the issue of convertible bonds, and anticipated future cash inflows in relation to commercial activities are considered sufficient to meet the Group's forecast cash outflows in relation to research and development activities currently underway and other committed business activities for at least 12 months from the date of this report.

On this basis, the Directors are satisfied that the Group continues to be a going concern as at the date of this report. Further, the Directors are of the opinion that no asset is likely to be realised for an amount less than the amount at which it is recorded in the interim consolidated statement of financial position as at 30 June 2024.

As such, no adjustment has been made to the financial report relating to the recoverability and classification of the asset carrying amounts or the classification of liabilities that might be necessary should the Group not continue as a going concern.

2.2. Significant changes in the prior reporting period

The Group updated the classification of expenses to make the consolidated statement of comprehensive income more relevant to users of the financial statements, particularly as a result of the Group acquiring new businesses during the period. This has resulted in the reclassification of some expenses for the period ended 30 June 2023, however has not impacted the reported profit or loss for the period or earnings per share.

From 2023, the Group has determined that a functional presentation of its consolidated statement of comprehensive income or loss is most appropriate. In accordance with IAS 1/AASB 101 *Presentation of Financial Statements*, within a functional consolidated statement of comprehensive income or loss, costs directly associated with generating revenues are included in cost of sales. Cost of sales includes direct material and labour costs, distribution fees incurred to ensure delivery of the product to the end customer and indirect costs that are directly attributed to generating revenue, such as amortisation of intangible assets associated with commercialised products.

In addition to the above, the Group has disclosed an additional line item of manufacturing and distribution costs on its consolidated statement of comprehensive income or loss. This line item represents departments and associated costs of the business that were previously included within selling and marketing expenses. These functions are ancillary in nature and indirectly support manufacturing, supply chain, logistics, facilities and quality activities.

3. Segment reporting

The Group has operations in the Americas, Asia Pacific, and Europe, Middle East and Africa regions.

Reportable segments

The Group operated four reportable segments during the half-year ended 30 June 2024. Medical Technologies and Manufacturing Services are reclassified from Unallocated to separately reportable segments from April 2024 following the acquisitions of ARTMS and IsoTherapeutics.

The Group's operating segments are based on the reports reviewed by the Group Chief Executive Officer who is considered to be the chief operating decision maker. The prior year comparatives have been restated on a consistent basis. There is no change to the total revenue or profit/(loss) after tax of the Group.

Segment performance is evaluated based on Adjusted earnings before interest, tax, depreciation and amortisation (Adjusted EBITDA[1]). Adjusted EBITDA excludes the effects of the remeasurement of contingent consideration and government grant liabilities and other income and expenses which may have an impact on the quality of earnings such as impairments where the impairment is the result of an isolated, non-recurring event. Interest income and finance costs are not allocated to segments as this activity is managed by a central treasury function, which manages the cash position of the Group.

Segment assets and liabilities are measured in the same way as in the financial statements. The assets and liabilities are allocated based on the operations of the segment. Finance costs are not allocated to segments, as this type of activity is driven by head office, which manages the cash position of the Group.

Reportable segment	Principal activities
Commercial	Commercial sales of Illuccix and other products subsequent to obtaining regulatory approvals.
Product development	Developing radiopharmaceutical products for commercialisation. This segment includes revenue received from licence agreements prior to commercialisation and research and development services.
Medical technologies	Developing complementary artificial intelligence (AI) and robotic technologies. This segment includes costs and assets associated with the Group's development of AI molecular imaging and guided robotic surgical technologies and includes Dedicaid, Lightpoint Surgical, and QDOSE.
Manufacturing services	Telix Manufacturing Solutions business. This segment comprises costs to operate our facilities and assets associated with the Group's vertically integrated manufacturing and supply chain. This business includes facilities at Brussels South, IsoTherapeutics, Optimal Tracers and ARTMS.

Reconciling items includes head office and centrally managed costs (which includes any remeasurements of contingent consideration liabilities).

1. Refer to the Glossary for a definition of this alternative performance measure.

3.1. Segment performance

30 June 2024	Commercial $'000	Product development $'000	Medical technologies $'000	Manufacturing services $'000	Total segment $'000
Revenue from contracts with customers	358,818	4,278	-	868	363,964
Cost of sales	(124,938)	-	-	-	(124,938)
Gross profit	**233,880**	**4,278**	**-**	**868**	**239,026**
Research and development costs	-	(83,890)	(284)	(16)	(84,190)
Selling and marketing expenses	(37,188)	-	-	(123)	(37,311)
Manufacturing and distribution costs	(5,071)	-	(182)	(8,074)	(13,327)
General and administration costs	(16,899)	-	(890)	(2,149)	(19,938)
Other losses (net)	229	-	-	65	294
Operating profit/(loss)	**174,951**	**(79,612)**	**(1,356)**	**(9,429)**	**84,554**
Other losses (net)	(229)	-	-	(65)	(294)
Depreciation and amortisation	2,726	55	5	541	3,327
Adjusted earnings before interest, tax, depreciation and amortisation	**177,448**	**(79,557)**	**(1,351)**	**(8,953)**	**87,587**

30 June 2023	Commercial $'000	Product development $'000	Medical technologies $'000	Manufacturing services $'000	Total segment $'000
Revenue from contracts with customers	218,516	2,042	-	276	220,834
Cost of sales	(81,791)	-	-	-	(81,791)
Gross profit	**136,725**	**2,042**	**-**	**276**	**139,043**
Research and development costs	-	(48,715)	-	(11)	(48,726)
Selling and marketing expenses	(24,171)	-	-	-	(24,171)
Manufacturing and distribution costs	(3,143)	-	-	(1,159)	(4,302)
General and administration costs	(14,024)	-	-	(1,626)	(15,650)
Other losses (net)	(1,248)	-	-	-	(1,248)
Operating profit/(loss)	**94,139**	**(46,673)**	**-**	**(2,520)**	**44,946**
Other losses (net)	1,248	-	-	-	1,248
Depreciation and amortisation	2,700	123	-	183	3,006
Adjusted earnings before interest, tax, depreciation and amortisation	**98,087**	**(46,550)**	**-**	**(2,337)**	**49,200**

3.2. Reconciliation of total segment adjusted EBITDA to profit/(loss) before income tax

	Note	30 June 2024 $'000	30 June 2023 $'000
Total segment adjusted EBITDA		**87,587**	**49,200**
Unallocated income and expenses:			
General and administration costs		(39,403)	(14,665)
Other losses (net)	4.6	(2,870)	(38,159)
Finance income		1,373	453
Finance costs		(8,678)	(6,123)
Depreciation and amortisation		(3,327)	(3,006)
Profit/(loss) before income tax		**34,682**	**(12,300)**

General and administration costs predominantly comprise of employment costs of $19,101,000 (30 June 2023: $7,172,000) and other centrally managed IT, legal and other corporate costs. Refer to note 4.3 for further details.

3.3. Operating segment assets and liabilities

30 June 2024	Commercial $'000	Product development $'000	Medical technologies $'000	Manufacturing services $'000	Total segment $'000	Reconciling items $'000	Group $'000
Total assets	181,286	181,748	55,630	212,599	**631,263**	114,695	**745,958**
Total liabilities	64,901	21,219	649	44,633	**131,402**	210,582	**341,984**
Additions to non-current assets	78	135,931	1,967	163,566	**301,542**	236	**301,778**

31 December 2023	Commercial $'000	Product development $'000	Medical technologies $'000	Manufacturing services $'000	Total segment $'000	Reconciling items $'000	Group $'000
Total assets	167,356	46,744	52,700	36,835	**303,635**	102,323	**405,958**
Total liabilities	65,890	40,252	275	20,172	**126,589**	130,458	**257,047**
Additions to non-current assets	12,025	5,116	54,296	-	**71,437**	-	**71,437**

Reconciling items primarily comprise cash and cash equivalents held centrally $67,251,000 (31 December 2023: $68,768,000), investments in financial assets $10,472,000 (31 December 2023: $12,260,000), property, plant and equipment $1,496,000 (31 December 2023: $3,942,000), tax assets and liabilities and contingent consideration liabilities (note 12) which are managed centrally.

Reportable segment total assets and total liabilities as at 31 December 2023 have been re-presented to reflect the reallocation of assets and liabilities relating to the Medical technologies and Manufacturing services segments and Group level adjustments between segments.

3.4. Geographical information

	30 June 2024	30 June 2023	30 June 2024	31 December 2023
	Revenue by location of customer	Revenue by location of customer	Non-current assets by location of asset	Non-current assets by location of asset
	$'000	$'000	$'000	$'000
Australia	523	426	26,805	21,057
Belgium	331	202	75,773	77,469
Canada	835	1,060	138,422	-
China	4,765	2,042	-	-
United Kingdom	236	1,101	51,497	50,346
United States	354,756	213,772	157,472	4,130
Other countries	2,518	2,231	4,029	-
Total	**363,964**	**220,834**	**453,998**	**153,002**

The total non-current assets figure above excludes deferred tax assets.

4. Profit and loss information

The Group has identified a number of items which are material due to the significance of their nature and/or amount. These are listed separately here to provide a better understanding of the financial performance of the Group.

4.1. Revenue from contracts with customers

Disaggregation of revenue from contracts with customers

The Group derives revenue from the sale and transfer of goods and services over time and at a point in time under the following major business activities:

			30 June 2024	30 June 2023
	Recognition	Operating segment	$'000	$'000
Sale of goods	At a point in time	Commercial	357,862	218,311
Royalty income	At a point in time	Commercial	956	205
Provision of services	Over time	Manufacturing services	868	276
Research and development services	Over time	Product development	4,278	2,042
Total revenue from continuing operations			**363,964**	**220,834**

4.2. Research and development costs

The following costs are included within research and development costs:

	30 June 2024	30 June 2023
	$'000	$'000
Late-stage diagnostics	33,972	18,509
Therapeutics and other assets	24,303	11,837
General and administration costs	6,190	3,568

4.3. General and administration costs

The following costs are included within general and administration costs

	30 June 2024	30 June 2023
	$'000	$'000
Professional fees	7,179	4,998
Acquisition related transaction costs	1,348	-
U.S. listing costs	7,618	-
IT infrastructure, hosting and support	3,415	2,267
Travel, conferences and entertainment	2,858	2,616
Rent and insurance	2,107	1,631
Marketing and sponsorship	1,465	1,218

General and administration costs incurred during the half-year includes costs associated with the withdrawn U.S. listing. Professional fees increased during the period primarily due to additional audit and review fees associated with the withdrawn U.S. listing.

Acquisition related transaction costs related to legal and professional fees associated with the acquisitions of IsoTherapeutics and ARTMS, refer to notes 10.1 and 10.2 for further details.

4.4. Employment costs

	30 June 2024	30 June 2023
	$'000	$'000
Salaries and wages	59,017	37,229
Short term incentives	6,264	4,955
Sales commissions	4,013	2,564
Share based payment charge	9,941	1,311
Superannuation	1,456	900
Non-Executive Directors' fees	379	292
	81,070	**47,251**

Salary and wages of $1,950,000 (30 June 2023: $553,000) are included within the cost of sales line item of the Interim consolidated statement of comprehensive income or loss.

4.5. Depreciation and amortisation

	30 June 2024	30 June 2023
	$'000	$'000
Amortisation of intangible assets	2,193	2,151
Depreciation	1,505	1,043
	3,698	**3,194**

4.6. Other losses (net)

	30 June 2024	30 June 2023
	$'000	$'000
Remeasurement of contingent consideration	3,071	36,054
Remeasurement of provisions	96	544
Realised currency gain	(87)	(2,117)
Other income	(342)	(1)
Unrealised currency loss	132	3,679
	2,870	**38,159**

4.7. Finance costs

	30 June 2024	30 June 2023
	$'000	$'000
Unwind of discount	8,006	5,681
Interest expense on lease liabilities	347	306
Interest expense	123	50
Bank fees	202	86
Finance costs	**8,678**	**6,123**

The Group recognised an unwind of discount on contingent consideration liabilities of $7,492,000 (30 June 2023: $4,981,000), an unwind of discount on provisions of $190,000 (30 June 2023: $197,000) and contract liabilities of $324,000 (30 June 2023: $503,000)

5. Trade and other receivables

	30 June 2024	31 December 2023
	$'000	$'000
Trade receivables	89,448	65,310
Allowance for impairment losses	(120)	(533)
	89,328	**64,777**

6. Inventories

	30 June 2024	31 December 2023
	$'000	$'000
Raw materials and stores	11,422	7,700
Work in progress	13,823	5,961
Finished goods	10,530	3,649
Provision for obsolesence	(4,972)	-
Total inventories	**30,803**	**17,310**

The amount of inventory recognised as an expense during the period was $15,694,000 (30 June 2023: $8,892,000).

Inventory manufactured as part of the Zircaix®[1] commercial manufacturing process qualification and validation has been capitalised as work in progress, with a corresponding provision for obsolesence recognised. This is on the basis that, prior to regulatory approval, the Group has not demonstrated that the batches produced can be sold commercially.

7. Financial assets

	2024	2023
	$'000	$'000
Investment in Mauna Kea	7,765	9,497
Investment in Atonco SAS	2,697	-
Investment in QSAM Biosciences[1]	-	2,763
Total financial assets	**10,462**	**12,260**

1. This investment was reclassified to intangible assets on completion of the QSAM asset acquisition, refer to note 10.3 for further details.

1. Brand name subject to final regulatory approval.

8. Property, plant and equipment

	Land and buildings	Plant and equipment	Furniture, fittings and equipment	Leasehold improvements	Total
	$'000	$'000	$'000	$'000	$'000
Balance at 1 January 2024	**20,442**	**499**	**680**	**1,549**	**23,170**
Additions	40	3,216	1,305	128	4,689
Acquisition of business	-	1,416	262	644	2,322
Reclassifications	-	(3)	(7)	(6)	(16)
Changes in provisions	(388)	-	-	-	(388)
Depreciation charge	-	(58)	(217)	(125)	(400)
Exchange differences	(264)	(82)	38	1	(307)
Balance at 30 June 2024	**19,830**	**4,988**	**2,061**	**2,191**	**29,070**
Cost	20,140	5,442	3,198	2,675	31,455
Accumulated depreciation	(310)	(454)	(1,137)	(484)	(2,385)
Net book amount	**19,830**	**4,988**	**2,061**	**2,191**	**29,070**
Balance as at 1 January 2023	**9,611**	**576**	**441**	**1,404**	**12,032**
Additions	8,912	96	168	503	9,679
Acquisition of business	-	37	-	-	37
Reclassifications	2,021	(12)	490	(142)	2,357
Depreciation charge	(91)	(207)	(422)	(222)	(942)
Exchange differences	(11)	9	3	6	7
Balance at 31 December 2023	**20,442**	**499**	**680**	**1,549**	**23,170**
Cost	20,752	895	1,600	1,908	25,155
Accumulated depreciation	(310)	(396)	(920)	(359)	(1,985)
Net book amount	**20,442**	**499**	**680**	**1,549**	**23,170**

9. Intangible assets

	Goodwill	Intellectual property	Customer relationships and brands	Software	Patents	Licences	Total
	$'000	$'000	$'000	$'000	$'000	$'000	$'000
Balance at 1 January 2024	**4,847**	**92,217**	**-**	**1,622**	**529**	**10,448**	**109,663**
Acquisition of business	113,876	39,938	1,382	-	-	-	155,196
Additions	-	135,931	-	1,967	-	-	137,898
Reclassifications	77	-	-	-	-	(77)	-
Amortisation charge	-	(1,976)	(61)	-	(7)	(149)	(2,193)
Changes in provisions	-	170	-	-	-	-	170
Exchange differences	(1,055)	(164)	(26)	15	(6)	(15)	(1,251)
Balance at 30 June 2024	**117,745**	**266,116**	**1,295**	**3,604**	**516**	**10,207**	**399,483**
Cost	117,745	289,879	1,356	3,604	951	11,501	425,036
Accumulated amortisation	-	(23,763)	(61)	-	(435)	(1,294)	(25,553)
Net book amount	**117,745**	**266,116**	**1,295**	**3,604**	**516**	**10,207**	**399,483**
Balance as at 1 January 2023	**5,519**	**41,060**	**-**	**-**	**300**	**12,105**	**58,984**
Additions	-	57,410	-	1,659	266	77	59,412
Reclassifications	-	-	-	-	-	(2,021)	(2,021)
Amortisation charge	-	(4,005)	-	-	(37)	(302)	(4,344)
Impairments	-	(804)	-	-	-	-	(804)
Changes in provisions	(672)	489	-	-	-	282	99
Exchange differences	-	(1,933)	-	(37)	-	307	(1,663)
Balance at 31 December 2023	**4,847**	**92,217**	**-**	**1,622**	**529**	**10,448**	**109,663**
Cost	4,847	114,048	-	1,622	949	11,604	133,070
Accumulated amortisation	-	(21,831)	-	-	(420)	(1,156)	(23,407)
Net book amount	**4,847**	**92,217**	**-**	**1,622**	**529**	**10,448**	**109,663**

The allocation of intangible assets to each cash-generating unit (CGU) is summarised below:

			30 June 2024	31 December 2023
Product or business unit	**Useful life**	**CGU**	**$'000**	**$'000**
TLX591-CDx (Illuccix®)	Definite	Commercial	8,915	10,876
QSAM (^{153}Sm-DOTMP)	Indefinite	Product development	134,821	-
TLX591	Indefinite	Product development	18,074	17,912
TLX66	Indefinite	Product development	15,739	15,569
TLX300	Indefinite	Product development	6,823	6,823
TLX101	Indefinite	Product development	1,531	1,613
Patents	Definite	Product development	515	529
ARTMS	Indefinite	Manufacturing services	135,254	-
IsoTherapeutics	Definite and indefinite	Manufacturing services	18,594	-
Brussels South and Optimal Tracers	Definite	Manufacturing services	4,153	4,298
SENSEI	Indefinite	Medical technologies	51,460	50,346
Dedicaid, QDOSE	Indefinite	Medical technologies	3,604	1,697
			399,483	**109,663**

Impairment trigger for goodwill and indefinite life intangible assets

The Group has considered reasonably possible changes in the key assumptions and has not identified any instances that could cause the carrying amounts of the intangible assets at 30 June 2024 to exceed their recoverable amounts. The intangible assets arising from the IsoTherapeutics and ARTMS acquisitions made during the half-year are provisional and subject to change within the 12 month measurement period, refer to note 10 for further details.

10. Acquisitions

10.1. IsoTherapeutics Group, LLC

On 9 April 2024 Telix completed the acquisition of IsoTherapeutics Group, LLC (IsoTherapeutics). IsoTherapeutics is a commercial-stage company that provides radiochemistry and bioconjugation development and contract manufacturing services to numerous companies in the radiopharmaceutical industry, including Telix.

The total consideration is $19,859,000 of which $8,912,000 has been paid in equity through the issue of 717,587 fully paid ordinary Telix shares at $12.42 per share, with $3,285,000 paid in cash. A further $7,662,000 is payable in cash for performance-related milestone payments that are subject to meeting milestone conditions within twelve months of closing.

Further performance-based payments are payable in cash to the IsoTherapeutics sellers based on 50% of net revenue during a two year revenue sharing period from the closing date. These payments are effectively a retention mechanism of key employees and as such are excluded from the acquisition consideration and instead will be recognised as an expense over the revenue sharing period within the Group's consolidated statement of comprehensive income.

The following table summarises the consideration paid for IsoTherapeutics, the fair value of assets acquired and liabilities assumed at the acquisition date. These balances are provisional and subject to change within the 12 month measurement period.

Consideration	Provisional fair value $'000
Cash paid	3,285
Equity issued	8,912
Contingent consideration	7,662
Total consideration	**19,859**
Recognised amounts of identifiable assets acquired and liabilities assumed	
Cash and cash equivalents	394
Trade and other receivables	642
Property, plant and equipment	365
Right-of-use assets	519
Trade and other payables	(7)
Lease liabilities	(519)
Total identifiable assets and liabilities	**1,394**
Fair value adjustments	
Customer relationships	1,280
Brand name	102
Deferred tax liabilities	(332)
Total fair value adjustments	**1,050**
Goodwill	17,415
Total	**19,859**

The goodwill arising is attributable to the acquired workforce, anticipated future cost savings from utilising IsoTherapeutics' manufacturing and radiopharmaceutical development capability and synergies of integrating the business within the Group. The goodwill arising from the acquisition has been allocated to the manufacturing services CGU.

Fair value adjustments have been recognised for acquisition-related intangible assets and related deferred tax.

Acquisition-related intangible assets of $1,280,000 relate to the valuation of the customer relationships and $102,000 relates to the value of the acquired IsoTherapeutics brand. The useful economic lives of each of these acquisition-related intangible assets is four and two years, respectively.

Acquisition costs of $1,272,000 have been charged to the statement of comprehensive income in the year relating to the acquisition of IsoTherapeutics.

IsoTherapeutics contributed $811,000 towards revenue and a net loss of $372,000 towards the Group's profit before tax attributable to equity holders of the parent for the period after the date of acquisition. As a preliminary assessment, had the acquisition of IsoTherapeutics been completed on the first day of the period, Group revenues would have been approximately $913,000 higher and Group profit before tax attributable to equity holders of the parent would have been approximately $261,000 lower.

10.2. ARTMS Inc.

On 11 April 2024 Telix completed the acquisition of radioisotope production technology firm ARTMS Inc. (ARTMS). ARTMS, based in Vancouver, BC (Canada), is a commercial-stage company, which specialises in the physics, chemistry and materials science of cyclotron-produced radionuclides.

The total consideration is $133,773,000 of which $71,610,000 has been paid in equity through the issue of 5,674,365 fully paid ordinary Telix shares at $12.62 per share, with $24,491,000 paid in cash.

A further $37,672,000 in contingent future milestone and royalty payments is payable in cash following achievement of certain clinical or commercial milestones and sales targets. The royalties represent a low single to low double-digit

percentage of net sales of ARTMS products or Telix products prepared using ARTMS products for defined periods depending on the product location where the sale occurs. All earn-outs which have not otherwise expired will terminate on the 10 year anniversary of completion.

The following table summarises the consideration paid for ARTMS, the fair value of assets acquired and liabilities assumed at the acquisition date. These balances are provisional and subject to change within the 12 month measurement period.

	Provisional fair value
Consideration	**$'000**
Cash paid	24,491
Equity issued	71,610
Contingent consideration	37,672
Total consideration	**133,773**
Recognised amounts of identifiable assets acquired and liabilities assumed	
Cash and cash equivalents	5,810
Trade and other receivables	252
Other current assets	67
Inventories	2,869
Other non-current assets	149
Property, plant and equipment	1,422
Right-of-use assets	1,154
Trade and other payables	(4,716)
Lease liabilities	(1,154)
Total identifiable assets and liabilities	**5,853**
Fair value adjustments	
Intellectual property	39,965
Deferred tax liabilities	(10,487)
Property, plant and equipment	504
Inventories	1,478
Total fair value adjustments	**31,460**
Goodwill	96,460
Total	**133,773**

The goodwill arising is attributable to the acquired workforce, anticipated future cost savings from utilising ARTMS' radioisotope production capabilities and synergies of vertically integrating the business within the Group. The goodwill arising from the acquisition has been allocated to the manufacturing services CGU.

Fair value adjustments have been recognised for acquisition-related intangible assets, property, plant and equipment, inventories and related deferred tax.

Acquisition-related intangible assets of $39,965,000 relate to the valuation of the acquired ARTMS intellectual property. The useful economic life of the intellectual property has not been assessed at the acquisition date, as the intellectual property is not available for commercial use until regulatory approval has been obtained.

Acquisition costs of $455,000 have been charged to the statement of comprehensive income in the year relating to the acquisition of ARTMS.

ARTMS contributed $36,000 towards revenue and a net loss of $2,320,000 towards the Group's profit before tax attributable to equity holders of the parent for the period after the date of acquisition. As a preliminary assessment, had the acquisition of ARTMS been completed on the first day of the period, Group revenues would have been approximately $305,000 higher and Group profit before tax attributable to equity holders of the parent would have been approximately $2,477,000 lower.

10.3. QSAM Biosciences, Inc.

On 3 May 2024 Telix completed of the acquisition of QSAM Biosciences, Inc. (QSAM) and its lead investigational drug Samarium-153-DOTMP (^{153}Sm-DOTMP). QSAM is a U.S. based company developing therapeutic radiopharmaceuticals for primary and metastatic bone cancer.

The upfront purchase price was $61,196,000 of which $54,470,000 was paid to QSAM in equity through the issue of 3,671,120 fully paid ordinary Telix shares and $6,726,000 paid in cash. 66,011 Telix shares, were held back against any adjustments required to be made post completion. These shares were issued in July.

A further US$90,000,000 in Contingent Value Rights, or performance rights, is payable in cash and/or in ordinary shares, upon achievement of certain clinical or commercial milestones.

The Group has determined that substantially all of the fair value of the gross assets acquired is concentrated in a single asset or a group of similar assets. The Group has applied the optional concentration of fair value test in IFRS 3/AASB 3 *Business Combinations* and concluded that the components acquired will be treated as an asset acquisition.

The performance rights have been recognised as an equity settled share based payment at a fair value of $67,943,000 which has been included in the fair value of intellectual property. Each milestone has a fixed dollar amount which can be settled either in cash or shares. The fair value of the performance rights was determined based on management's assessment of the likelihood of each milestone being reached against the fixed dollar amount for that milestone. The likelihood of the milestones being attained are considered non-vesting conditions as there are no further services or obligations of the counterparty, thus being reflected in the fair value.

The fair values of identifiable assets on acquisition are outlined below:

	Fair value
Consideration	**$'000**
Cash paid	6,726
Equity issued	54,470
Performance rights issued	67,943
Total consideration	**129,139**
Recognised amounts of identifiable assets acquired and liabilities assumed	
Cash and cash equivalents	18
Trade and other receivables	52
Intellectual property	129,907
Trade and other payables	(838)
Total identifiable assets and liabilities	**129,139**

Acquisition costs of $5,863,000 have been capitalised to the intellectual property recognised, as the costs were directly attributable to preparing the intellectual property for its intended use.

11. Trade and other payables

	30 June 2024	31 December 2023
	$'000	$'000
Trade creditors	22,302	32,837
Accruals	51,878	37,895
Other creditors	5,678	6,738
Accrued royalties	1,846	3,205
Payroll liabilities	2,008	899
Government rebates payable	565	130
Total trade and other payables	**84,277**	**81,704**

12. Contingent consideration

	ANMI	TheraPharm	Optimal Tracers	IsoTherapeutics	ARTMS	Total
	$'000	$'000	$'000	$'000	$'000	$'000
Balance at 1 January 2024	**90,493**	**2,178**	**83**	**-**	**-**	**92,754**
Remeasurement of contingent consideration	3,071	-	-	-	-	3,071
Unwind of discount	6,631	144	-	-	717	7,492
Charged to profit or loss	**9,702**	**144**	**-**	**-**	**717**	**10,563**
Exchange differences	1,919	(12)	4	(144)	(362)	1,405
Acquisition of business	-		-	7,662	37,672	45,334
Amounts adjusted to intangible assets	-	170	-	-	-	170
Payments for contingent consideration	-	-	(49)	-	-	(49)
Balance at 30 June 2024	**102,114**	**2,480**	**38**	**7,518**	**38,027**	**150,177**
Current	102,114	-	38	7,518	-	109,670
Non-current	-	2,480	-	-	38,027	40,507
Total contingent consideration	**102,114**	**2,480**	**38**	**7,518**	**38,027**	**150,177**
Balance at 1 January 2023	**62,541**	**1,690**	**-**	**-**	**-**	**41,910**
Remeasurement of contingent consideration	34,275	-	-	-	-	34,275
Unwind of discount	11,033	278	83	-	-	11,394
Charged to profit or loss	**45,308**	**278**	**83**	**-**	**-**	**45,669**
Exchange differences	410	(279)	(46)	-	-	4,201
Acquisition of business	-	-	718	-	-	718
Amounts adjusted to intangible assets	-	489	(672)	-	-	256
Payments for contingent consideration	(17,766)	-	-	-	-	-
Balance at 31 December 2023	**90,493**	**2,178**	**83**	**-**	**-**	**92,754**
Current	37,070	-	83	-	-	37,153
Non-current	53,423	2,178	-	-	-	55,601
Total contingent consideration	**90,493**	**2,178**	**83**	**-**	**-**	**92,754**

12.1. Telix Innovations (formerly ANMI)

The Group acquired Telix Innovations on 24 December 2018. The Group is liable for future variable payments which are calculated based on the percentage of net sales for five years following the achievement of market authorisation of Illuccix® (TLX591-CDx). The percentage of net sales varies depending on the net sales achieved in the U.S. and the rest of the world. The Group also holds an option to buy-out the remaining future variable payments in the third year following the achievement of market authorisation, if specified sales thresholds are met.

As at the consolidated statement of financial position date, the Group has remeasured the contingent consideration to its fair value. The remeasurement is as a result of changes to the key assumptions such as the risk adjusted post-tax discount rate, expected sales volumes and net sales price per unit.

The contingent consideration liability has been valued using a discounted cash flow model that utilises certain unobservable Level 3 inputs. These key assumptions include risk adjusted post-tax discount rate of 13.0% (31 December 2023: 15.0%), expected sales volume over the forecast period and net sales price per unit.

Refer to the Group's 2023 Annual Report for further quantitative information about these assumptions, including the impact of sensitivities from reasonably possible changes where applicable.

12.2. IsoTherapeutics

The Group acquired IsoTherapeutics on 9 April 2024. The Group is liable for $7,662,000 which is payable in cash for performance-related milestone payments that are subject to meeting milestone conditions within twelve months of closing.

The contingent consideration liability has not been discounted as it is due within twelve months.

12.3. ARTMS

Telix acquired ARTMS on 11 April 2024. Part of the consideration for the acquisition was in the form of future payments contingent on certain milestones. These are:

Milestone	Amount (US$)
Approval by the FDA and subsequent direct incorporation of the ARTMS Technology into the U.S. Telix Illuccix approved product labels	$4,500,000
Upon completion of the installation and acceptance of a target number of ARTMS QIS systems in commercial radiopharmacy sites in the U.S.	$5,000,000
Upon achieving cumulative Net Sales from consumables	$5,000,000
Upon achieving cumulative annual Net Sales from sales of ARTMS Products and consumables	$5,000,000
Upon achieving a cumulative total target Net Sales from ARTMS Products, inclusive of QIS installations, processing systems, QUANTM targets and consumable Net Sales	$5,000,000

In addition to the above, the contingent consideration includes future royalty payments for a low single to low double-digit percentage of net sales of ARTMS products or Telix products.

The contingent consideration liability has been valued using a discounted cash flow model that utilises certain unobservable Level 3 inputs. These key assumptions include risk adjusted post-tax discount rate at acquisition of 15.0%, FDA approval dates, expected sales volume over the forecast period and net sales price per unit.

The following table summarises the quantitative information about these assumptions, including the impact of sensitivities from reasonably possible changes where applicable:

Contingent consideration valuation

Unobservable input	Methodology	30 June 2024
Risk adjusted post-tax discount rate	The post-tax discount rate used in the valuation has been determined based on required rates of returns of listed companies in the biotechnology industry (having regards to their stage of development, size and risk adjustments).	A 0.5% increase in the post-tax discount rate would decrease the contingent consideration by 0.9% and a 0.5% decrease in the post-tax discount rate would increase the contingent consideration by 0.9%.
Expected sales volumes - ARTMS and Telix products	This is determined through assumptions on target market population, penetration and growth rates in the United States and Europe.	A 10.0% increase in the sales volumes would increase the contingent consideration by 10.0% and a 10.0% decrease in sales volumes would decrease the contingent consideration by 10.0%.
Net sales price per unit	The net sales price per unit is estimated based on comparable products currently in the market.	A 10.0% increase in the net sales price per unit would increase the contingent consideration by 10.0% to 21.0% across the different royalties and a 10.0% decrease in net sales price per unit would decrease the contingent consideration by 10.0% to 21.0% across the different royalties.

13. Contractual maturities of financial liabilities

As at 30 June 2024, the contractual maturities of the Group's non-derivative financial instrument liabilities are outlined below. The tables have been drawn up based on the undiscounted cash flows of financial liabilities based on the earliest date on which the financial liabilities are required to be paid. The tables include both interest and principal cash flows disclosed as remaining contractual maturities and therefore these totals may differ from their carrying amount in the consolidated statement of financial position.

	1-6 months	6-12 months	1-5 years	Over 5 years	Total contractual cash flows	Carrying amount of liabilities
As at 30 June 2024	**$'000**	**$'000**	**$'000**	**$'000**	**$'000**	**$'000**
Non-derivatives						
Trade and other payables	84,277	-	-	-	84,277	84,277
Borrowings	1,095	1,095	8,763	5,705	16,658	11,852
Lease liabilities	1,492	1,469	8,497	538	11,996	10,291
Government grant liability	372	752	1,675	678	3,477	3,014
Contingent consideration	39,836	75,774	52,382	2,359	170,351	150,177
Total financial liabilities	**127,072**	**79,090**	**71,317**	**9,280**	**286,759**	**259,611**

As at 31 December 2023, the contractual maturities of the Group's non-derivative financial liabilities were as follows:

	1-6 months	6-12 months	1-5 years	Over 5 years	Total contractual cash flows	Carrying amount of liabilities
As at 31 December 2023	**$'000**	**$'000**	**$'000**	**$'000**	**$'000**	**$'000**
Non-derivatives						
Trade and other payables	81,704	-	-	-	81,704	81,704
Borrowings	1,105	1,105	8,839	6,859	17,908	9,173
Lease liabilities	1,044	1,057	6,744	1,264	10,109	8,272
Government grant liability	376	577	3,169	593	4,715	2,664
Contingent consideration	-	38,382	65,229	2,352	105,963	92,754
Total financial liabilities	**84,229**	**41,121**	**83,981**	**11,068**	**220,399**	**194,567**

14. Equity

14.1. Share capital

	30 June 2024	31 December 2023	30 June 2024	31 December 2023
	Number '000	Number '000	$'000	$'000
Opening balance	**323,727**	**316,343**	**446,268**	**370,972**
Shares issued through the exercise of share options and warrants[1]	441	3,879	6,148	42,572
Shares issued for Dedicaid[2]	-	207	-	1,829
Shares issued for Lightpoint[3]	-	3,298	-	30,895
Shares issued for IsoTherapeutics[4]	718	-	8,912	-
Shares issued for ARTMS[5]	5,675	-	71,610	-
Shares issued for QSAM[6]	3,671	-	54,470	-
Closing balance	**334,232**	**323,727**	**587,408**	**446,268**

1. Options exercised during the half-year through the employee Equity Incentive Plan resulted in 441,373 (31 December 2023: 3,878,633) shares being issued for a total value of $6,148,000 (31 December 2023: $42,572,000).
2. On 27 April 2023, the Group completed the acquisition of Dedicaid. The consideration for the acquisition comprised an upfront payment of $1,829,000 (€1,100,000) in Telix shares at a fair value of A$8.73 per share (207,207 Telix shares).
3. On 1 November 2023, the Group completed the acquisition of Lightpoint through the issue of 3,298,000 fully paid ordinary Telix shares at $9.3659 per share.
4. On 9 April 2024, the Group completed the acquisition of IsoTherapeutics. The consideration included the issue of 717,587 fully paid ordinary Telix shares at AU$12.42 per share.
5. On 11 April 2024, the Group completed the acquisition of ARTMS. The consideration included the issue of 5,674,365 fully paid ordinary Telix shares at AU$12.62 per share.
6. On 3 May 2024, the Group completed the acquisition of QSAM. The purchase price included the issue of 3,671,120 fully paid ordinary Telix shares at AU$14.80 per share.

The weighted average ordinary shares for the period 1 January 2024 to 30 June 2024 is 327,726,673 (31 December 2023: 319,180,783). The Company does not have a limited amount of authorised capital.

14.2. Share-based payments reserve

	30 June 2024	31 December 2023	30 June 2024	31 December 2023
	Number '000	Number '000	$'000	$'000
Opening balance	**14,601**	**11,736**	**35,446**	**9,321**
EIP options issued	3,715	6,689	9,941	8,786
Performance Rights issued[1]	4,284	2,524	67,943	21,278
Options exercised	(520)	(4,524)	(507)	(3,939)
Options lapsed	(1,495)	(1,824)	-	-
Closing balance	**20,585**	**14,601**	**112,823**	**35,446**

1. Relates to the acquisition of QSAM in the current period and Lightpoint in the prior year.

15. Commitments and contingent liabilities

15.1. Commitments

At 30 June 2024, the Group had commitments against existing R&D costs and capital commitments relating to the construction of the Brussels South radiopharmaceutical production facility. R&D commitments in future years are estimated based on the contractual obligations included within agreements entered into by the Group. These R&D

contracts have typical termination provisions to limit the commitment to the time and materials expended at termination, the orderly close out of activities or up to an approved work order amount.

	Due < 1 year	Due > 1 year
	$'000	$'000
30 June 2024		
Capital commitments[1]	22,407	35,191
R&D commitments	24,446	23,259
	46,853	**58,450**
31 December 2023		
Capital commitments	16,572	40,000
R&D commitments	28,112	20,403
	44,684	**60,403**

1. Includes the three year supply of Ytterbium-176 isotope.

15.2. Contingent liabilities and contingent assets

Refer to the Group's 2023 Annual Report for further details of existing agreements that could give rise to contingent liabilities. The Group has entered into a number of agreements with other third parties pertaining to intellectual property. Contingent liabilities may arise in the future if certain events or developments occur in relation to these agreements and as of 30 June 2024 we have assessed the likelihood of these contingent liabilities arising to be remote.

16. Related party transactions

16.1. Transactions with other related parties

In March 2024, the Group entered into an agreement to purchase the QDOSE dosimetry software platform from ABX-CRO. QDOSE is a software platform designed to enable reliable estimation of patient-specific dosimetry for both therapeutic and diagnostic radiopharmaceuticals. We agreed to pay ABX-CRO upfront cash consideration of €1,200,000, a share of profits generated from QDOSE sales and a referral fee on deals referred from or initiated by ABX-CRO over a 2-year period from acquisition.

Dr Andreas Kluge, Non-Executive Director, is the principal owner and Geschäftsführer (Managing Director) of ABX-CRO, a clinical research organisation (CRO) that specialises in radiopharmaceutical product development. QDOSE was independently valued as part of the acquisition negotiation process to ensure the proposed consideration was at an arms' length basis.

17. Events occurring after the reporting period

On 30 July 2024 the Group completed the issue of $650,000,000 in convertible bonds maturing in 2029. The convertible bonds are convertible into fully paid ordinary shares in Telix Pharmaceuticals Limited. The initial conversion price of the convertible bonds is $24.78 per share, subject to anti-dilution adjustments set out in the final terms and conditions of the convertible bonds. The convertible bonds will bear interest at a rate of 2.375 per cent per annum. Interest will be payable quarterly in arrears on 30 October, 30 January, 30 April and 30 July in each year, beginning on 30 October 2024. The convertible bonds will mature on or about 30 July 2029, unless redeemed, repurchased, or converted in accordance with their terms. The convertible bonds are listed on the Singapore Exchange Securities Trading Limited (SGX-ST).

The net proceeds of approximately $635,000,000, after transaction costs, are intended to provide funding to bring forward proposed investment in order to accelerate key clinical development programs across the Company's theranostic portfolio. This includes label-expansion studies to expand the market opportunity across Telix's portfolio of diagnostic imaging agents and funding the pivotal trials for kidney and brain cancer therapy programs. In addition, the funding will provide financial flexibility for Telix to explore opportunities and potentially pursue strategically significant M&A transactions and continued investment in global supply chain and manufacturing capabilities.

From the end of the reporting period to the date of this report, there were no other matters or circumstances which have significantly affected, or may significantly affect, the operations of the Group, the results of those operations or the state of affairs of the Group.

Directors' declaration

In the opinion of the Directors:

a. the financial statements and notes of the Group are in accordance with the *Corporations Act 2001 (Cth)*, including:
   i. giving a true and fair view of the Group's financial position as at 30 June 2024 and of its performance for the half-year ended on that date; and
   ii. complying with Accounting Standards, the Corporations Regulations 2001 and other mandatory professional reporting requirements; and
b. there are reasonable grounds to believe that the Company will be able to pay its debts as and when they become due and payable.

This declaration is made in accordance with a resolution of the Directors and has been made after receiving the declarations by the Chief Executive Officer and Chief Financial Officer and as recommended under the ASX Corporate Governance Council's Corporate Governance Principles and Recommendations for the half-year ended 30 June 2024.

H Kevin McCann AO
Chairman
22 August 2024

Christian Behrenbruch
Managing Director and Group CEO
22 August 2024

Independent auditor's review report to the members of Telix Pharmaceuticals Limited

Report on the half-year financial report

Conclusion

We have reviewed the half-year financial report of Telix Pharmaceuticals Limited (the Company) and the entities it controlled during the half-year (together the Group), which comprises the interim consolidated statement of financial position as at 30 June 2024, the interim consolidated statement of comprehensive income or loss, interim consolidated statement of changes in equity and interim consolidated statement of cash flows for the half-year ended on that date, material accounting policy information and explanatory notes and the directors' declaration.

Based on our review, which is not an audit, we have not become aware of any matter that makes us believe that the accompanying half-year financial report of Telix Pharmaceuticals Limited does not comply with the *Corporations Act 2001* including:

1. giving a true and fair view of the Group's financial position as at 30 June 2024 and of its performance for the half-year ended on that date

2. complying with Accounting Standard AASB 134 *Interim Financial Reporting* and the *Corporations Regulations 2001*.

Basis for conclusion

We conducted our review in accordance with ASRE 2410 *Review of a Financial Report Performed by the Independent Auditor of the Entity* (ASRE 2410). Our responsibilities are further described in the *Auditor's responsibilities for the review of the half-year financial report* section of our report.

We are independent of the Group in accordance with the auditor independence requirements of the *Corporations Act 2001* and the ethical requirements of the Accounting Professional & Ethical Standards Board's APES 110 *Code of Ethics for Professional Accountants (including Independence Standards)* (the Code) that are relevant to the audit of the annual financial report in Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code.

Responsibilities of the directors for the half-year financial report

The directors of the Company are responsible for the preparation of the half-year financial report that gives a true and fair view in accordance with Australian Accounting Standards and the *Corporations Act 2001* and for such internal control as the directors determine is necessary to enable the preparation of the half-year financial report that gives a true and fair view and is free from material misstatement whether due to fraud or error.

PricewaterhouseCoopers, ABN 52 780 433 757
2 Riverside Quay, SOUTHBANK VIC 3006, GPO Box 1331, MELBOURNE VIC 3001
T: 61 3 8603 1000, F: 61 3 8603 1999

Auditor's responsibilities for the review of the half-year financial report

Our responsibility is to express a conclusion on the half-year financial report based on our review. ASRE 2410 requires us to conclude whether we have become aware of any matter that makes us believe that the half-year financial report is not in accordance with the *Corporations Act 2001* including giving a true and fair view of the Group's financial position as at 30 June 2024 and of its performance for the half-year ended on that date, and complying with Accounting Standard AASB 134 *Interim Financial Reporting* and the *Corporations Regulations 2001*.

A review of a half-year financial report consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Australian Auditing Standards and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Matters relating to the electronic presentation of the reviewed half-year financial report

This review report relates to the half-year financial report of the Company for the half-year ended 30 June 2024 included on Telix Pharmaceuticals Limited's website. The Company's directors are responsible for the integrity of the Telix Pharmaceuticals Limited website. We have not been engaged to report on the integrity of this website. The review report refers only to the statements named above. It does not provide a conclusion on any other information which may have been hyperlinked to/from these statements. If users of this report are concerned with the inherent risks arising from electronic data communications they are advised to refer to the hard copy of the reviewed half-year financial report to confirm the information included in the reviewed half-year financial report presented on this website.

PricewaterhouseCoopers

Brad Peake
Partner

Melbourne
22 August 2024

Alternative performance measures (APMs)

The Group believes that Adjusted earnings before interest, tax, depreciation and amortisation (Adjusted EBITDA), Adjusted earnings before interest, tax and research and development (Adjusted EBITRD), Adjusted earnings before interest, tax, depreciation, amortisation and research and development (Adjusted EBITDAR), net working capital and net tangible assets per share provide useful information to users of the financial statements. The terms are not defined terms under International Financial Reporting Standards (IFRS) and may therefore not be comparable with similarly titled measures reported by other companies. They are not intended to be a substitute for, or superior to, IFRS measures and are discussed further in the Glossary.

Outlined below is a reconciliation of the Group's APMs used to measure performance.

			30 June 2024	30 June 2023
Metric	**Note**	**Operating segment**	**$'000**	**$'000**
Operating profit			41,987	(6,630)
Adjusting items:				
Revenue from contracts with customers	4.1	Product development	(4,278)	(2,042)
Research and development costs		Product development	83,835	48,592
U.S. listing costs			7,618	-
Acquisition related transaction costs			1,348	-
Other losses (net)			2,870	38,159
Adjusted EBITRD			**133,380**	**78,079**
Depreciation and amortisation			3,698	3,194
Adjusted EBITDAR			**137,078**	**81,273**
Product development revenue and costs			(79,557)	(46,550)
Adjusted EBITDA			**57,521**	**34,723**

Glossary

Alternative performance measures

In reporting financial information, the Group presents alternative performance measures (APMs) which are not defined or specified under the requirements of IFRS. The Group believes that these APMs, which are not considered to be a substitute for or superior to IFRS measures, provide stakeholders with additional useful information on the underlying trends, performance and position of the Group and are consistent with how business performance is measured internally. The alternative performance measures are not defined by IFRS and therefore may not be directly comparable with other companies' alternative performance measures. The key APMs that the Group uses are outlined below.

APM	Closest equivalent IFRS measure	Reconciling items to IFRS measure	Definition and purpose
Income statement measures			
Adjusted earnings before interest, tax, depreciation and amortisation (Adjusted EBITDA)	Loss before income tax	Finance costs, depreciation and amortisation, remeasurement of provisions, U.S. Listing costs, transaction costs associated with acquisitions and other losses.	Used to help assess current operational performance excluding the impacts of non-cash sunk costs (i.e. depreciation and amortisation from initial investment in tangible and intangible assets). It is a measure that management uses internally to assess the performance of the Group's segments and make decisions on the allocation of resources.
Adjusted earnings before interest, tax, depreciation, amortisation and research and development (Adjusted EBITDAR)	Loss before income tax	Finance costs, depreciation and amortisation, remeasurement of provisions, U.S. Listing costs, transaction costs associated with acquisitions, other losses and revenue and costs associated with product development activities.	Used to assess the Group's performance excluding non-operating expenditure, finance costs, depreciation and amortisation and product development activities. Included as a metric for LTVR targets.
Adjusted earnings before interest, tax, research and development (Adjusted EBITRD)	Loss before income tax	Finance costs, remeasurement of provisions, U.S. Listing costs, transaction costs associated with acquisitions, other losses and revenue and costs associated with product development activities.	Used to assess the Group's performance excluding non-operating expenditure, finance costs and product development activities. Included as a metric for LTVR targets in 2022.
Balance sheet measures			
Net working capital	None	The total of cash and cash equivalents, inventory and current trade and other receivables less current trade and other payables.	Used to monitor the Group's working capital management and short-term liquidity.
Net tangible asset per share	None	Net assets excluding intangible assets, deferred tax assets and right-of-use assets divided by the Group's weighted average number of ordinary shares on issue.	Disclosed in the Group's Appendix 4E as required by Rule 4.3A of the ASX listing rules.

Abbreviations used in Interim Report

We have outlined below the meaning of various abbreviations or acronyms used in the Interim Report.

Abbreviation	Term
AASB	Australian Accounting Standards Board
AHPRA	Australian Health Practitioner Regulation Agency
AI	Artificial intelligence
AML	Acute myeloid leukaemia
APPI	Japanese Act on the Protection of Personal Information
ARC	Audit and Risk Committee
ASIC	Australian Securities and Investments Commission
ASX	Australian Securities Exchange

Abbreviation	Term
AutoML	Automatic machine-learning
BBB	Blood-brain barrier
BLA	Biologics License Application
BMC	Bone marrow conditioning
CAIX	Carbonic anhydrase IX
ccRCC	Clear cell renal cell carcinoma
CD66	Cluster of differentiation 66
CDSS	Clinical decision support software
CE	Conformité Européenne Mark
CNS	Central nervous system
DNA-PK	DNA-dependent protein kinase
EAP	Expanded access program
EBRT	External beam radiation therapy
ERMF	Enterprise Risk Management Framework
ESG	Environment, Social and Governance
FANC	Belgian Federal Agency for Nuclear Control
FDA	United States Food and Drug Administration
GBM	Glioblastoma multiforme
GCP	Good Clinical Practice
GDP	Good Distribution Practice
GDPR	General Data Protection Regulation
GET	Group Executive Team
GHG	Greenhouse gas
GLF	Global Leadership Forum
GLP	Good Laboratories Practice
GMP	Good Manufacturing Practice
GRC	Governance, Risk and Compliance
GSRC	Global Safety Review Committee
HIPAA	US Health Insurance Portability and Accountability Act
HSCT	Hematopoietic stem cell transplant
HSWE	Health, safety, wellbeing and environment
IAEA	International Atomic Energy Agency
ICRP	International Commission of Radiological Protection
IIT	Investigator initiated trial
IND	Investigational new drug
IPO	Initial Public Offering
ISMS	Information Security and Information Management
ISSB	International Sustainability Standards Board
KMP	Key management personnel
LAT1 & 2	L-type amino acid transporters 1 & 2
MBS	Medicare Benefits Schedule
mCRPC	Metastatic castration-resistant prostate cancer
MM	Multiple myeloma
MRI	Magnetic resonance imaging
NDA	New Drug Application
NED	Non-Executive Director
NPP	Named patient program
ODD	Orphan drug designation
PCNRC	People, Culture, Nomination and Remuneration Committee
PDGFRα	Platelet-derived growth factor receptor alpha
PMDA	Pharmaceuticals and Medical Devices Agency (Japan)
PoC	Proof-of-concept
PSA	Prostate-specific antigen
PSMA	Prostate-specific membrane antigen

Abbreviation	Term
PSMA-PET	Prostate-specific membrane antigen imaging with positron emission tomography
QMS	Quality Management System
QSEB	Quality and Safety Evaluation Board
R&D	Research and development
R&I	Research and Innovation
rADC	Radio antibody-drug conjugate
REACH	Registration, Evaluation and Authorisation of Chemicals
RGS	Radio-guided surgery
SALA	Systemic amyloid light chain amyloidosis
SLN	Sentinel lymph node
SoC	Standard of care
SOP	Standard operating procedure
SPECT	Single photon emission computed tomography
STS	Soft tissue sarcoma
TAT	Targeted alpha therapy
TGA	Therapeutic Goods Administration (Australia)
TMS	Telix Manufacturing Solutions
TNBC	Triple-negative breast cancer

Company directory

Company Secretary

Genevieve Ryan

Investor Relations and Corporate Communications

Kyahn Williamson

Registered Office

Telix Pharmaceuticals Limited
55 Flemington Road
North Melbourne VIC 3051
info@telixpharma.com
www.telixpharma.com

Australian Business Number

85 616 620 369

Securities Exchange Listing

Australian Securities Exchange
ASX Code: TLX

Auditor

PricewaterhouseCoopers
2 Riverside Quay
Southbank VIC 3006

Share Registry

Link Market Services Limited
Locked Bag A14
Sydney South NSW 1235
Australia
P: 1300 554 474
F: (02) 9287 0303
www.linkmarketservices.com.au